HomeCompareMPSFF vs JNJ

MPSFF vs JNJ: Dividend Comparison 2026

MPSFF yields 1052.63% · JNJ yields 2.14%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MPSFF wins by $29512389.25M in total portfolio value
10 years
MPSFF
MPSFF
● Live price
1052.63%
Share price
$0.19
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$29512389.28M
Annual income
$24,865,533,772,207.38
Full MPSFF calculator →
JNJ
Johnson & Johnson
● Live price
2.14%
Share price
$242.49
Annual div
$5.20
5Y div CAGR
28%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.5K
Annual income
$4,749.88
Full JNJ calculator →

Portfolio growth — MPSFF vs JNJ

📍 MPSFF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMPSFFJNJ
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MPSFF + JNJ cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MPSFF pays
JNJ pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MPSFF
Annual income on $10K today (after 15% tax)
$89,473.68/yr
After 10yr DRIP, annual income (after tax)
$21,135,703,706,376.27/yr
JNJ
Annual income on $10K today (after 15% tax)
$182.28/yr
After 10yr DRIP, annual income (after tax)
$4,037.40/yr
At 15% tax rate, MPSFF beats the other by $21,135,703,702,338.88/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MPSFF + JNJ for your $10,000?

MPSFF: 50%JNJ: 50%
100% JNJ50/50100% MPSFF
Portfolio after 10yr
$14756194.66M
Annual income
$12,432,766,888,478.63/yr
Blended yield
84.25%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on JNJ right now

MPSFF
No analyst data
JNJ
Analyst Ratings
20
Buy
17
Hold
3
Sell
Consensus: Buy
Price Target
$228.73
-5.7% upside vs current
Range: $190.00 — $265.00
Altman Z
5.2
Piotroski
4/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MPSFF buys
0
JNJ buys
0
No recent congressional trades found for MPSFF or JNJ in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMPSFFJNJ
Forward yield1052.63%2.14%
Annual dividend / share$2.00$5.20
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%28%
Portfolio after 10y$29512389.28M$30.5K
Annual income after 10y$24,865,533,772,207.38$4,749.88
Total dividends collected$29159831.22M$15.6K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: MPSFF vs JNJ ($10,000, DRIP)

YearMPSFF PortfolioMPSFF Income/yrJNJ PortfolioJNJ Income/yrGap
1← crossover$115,963$105,263.16$10,594$274.49+$105.4KMPSFF
2$1,264,889$1,140,808.24$11,294$360.69+$1.25MMPSFF
3$12,982,935$11,629,504.04$12,133$476.91+$12.97MMPSFF
4$125,449,028$111,557,287.82$13,156$635.42+$125.44MMPSFF
5$1,141,645,861$1,007,415,400.94$14,432$854.61+$1141.63MMPSFF
6$9,789,747,608$8,568,186,536.38$16,056$1,162.76+$9789.73MMPSFF
7$79,141,579,327$68,666,549,386.16$18,175$1,604.53+$79141.56MMPSFF
8$603,475,154,069$518,793,664,189.69$21,009$2,252.68+$603475.13MMPSFF
9$4,342,855,615,350$3,697,137,200,495.55$24,911$3,229.73+$4342855.59MMPSFF
10$29,512,389,280,631$24,865,533,772,207.38$30,458$4,749.88+$29512389.25MMPSFF

MPSFF vs JNJ: Complete Analysis 2026

MPSFFStock

RevoluGROUP Canada Inc., through its subsidiaries, provides technology solutions in the Americas, Europe, and internationally. The company offers RevoluPAY, the company's flagship Apple and Android multinational remittance app; RevoluVIP, a members only travel club; RevoluCHARGE, a pay-as-you go mobile top-up application; RevolUTILITY, a utility bills payment solution; RevoluREALTY, a solution for the payment of real estate related transactions, forex settlement, and closing fees to multiple beneficiaries; and RevoluMED, a solution for healthcare appointment scheduling, RX payment, pharmacy payments, medical insurance, insurance copay, and other financial aspects related to the healthcare industry. It also provides RevoluFIN, which offers bridge loans and factoring to corporations; RevoluEGAME for online video gaming, and selection and payment of mobile/console-based games and in-game play; RevoluESPORTS for eSports sector; RevoluSEND, a remittance platform; RevoluEX, a digital currency exchange solution; RevoluTRANSFER, an online money transfer solution; and RevoluPOS, a point of sale platform. In addition, the company engages in the online travel agency and digital media marketing businesses that cover travel marketing, electronic reservations, travel membership sales, and online booking solutions. It deploys technology solutions in the online travel, vacation forex, money remittance, mobile payment apps, mobile phone top-up, utility bill and healthcare payments, e-gaming, e-sports, online credits and gifts cards, real estate payments, blockchain security, invoice factoring and alternative lending, and POS merchant provider in personal and corporate leisure sectors. The company was formerly known as CUV Ventures Corp. and changed its name to RevoluGROUP Canada Inc. in November 2019. RevoluGROUP Canada Inc. was incorporated in 1980 and is headquartered in Burnaby, Canada.

Full MPSFF Calculator →

JNJHealthcare

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.

Full JNJ Calculator →
📬

Get this MPSFF vs JNJ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MPSFF vs SCHDMPSFF vs JEPIMPSFF vs OMPSFF vs KOMPSFF vs MAINMPSFF vs ABBVMPSFF vs MRKMPSFF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.